X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with ALEMBIC LTD - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs ALEMBIC LTD - Comparison Results

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA ALEMBIC LTD AJANTA PHARMA/
ALEMBIC LTD
 
P/E (TTM) x 24.5 121.4 20.2% View Chart
P/BV x 10.1 4.5 223.8% View Chart
Dividend Yield % 0.6 0.2 239.1%  

Financials

 AJANTA PHARMA   ALEMBIC LTD
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
ALEMBIC LTD
Mar-16
AJANTA PHARMA/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs1,72053 3,257.6%   
Low Rs1,10329 3,764.5%   
Sales per share (Unadj.) Rs194.64.7 4,123.3%  
Earnings per share (Unadj.) Rs45.28.8 515.4%  
Cash flow per share (Unadj.) Rs50.39.0 558.6%  
Dividends per share (Unadj.) Rs8.000.15 5,333.3%  
Dividend yield (eoy) %0.60.4 155.1%  
Book value per share (Unadj.) Rs132.027.7 476.2%  
Shares outstanding (eoy) m88.77267.03 33.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.38.7 83.4%   
Avg P/E ratio x31.24.7 667.1%  
P/CF ratio (eoy) x28.14.6 615.5%  
Price / Book Value ratio x10.71.5 722.1%  
Dividend payout %17.71.7 1,034.8%   
Avg Mkt Cap Rs m125,29910,962 1,143.1%   
No. of employees `000NANA-   
Total wages/salary Rs m2,570238 1,079.8%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m17,2751,260 1,370.7%  
Other income Rs m166264 63.0%   
Total revenues Rs m17,4421,524 1,144.4%   
Gross profit Rs m5,80783 7,013.5%  
Depreciation Rs m45161 733.9%   
Interest Rs m490 16,300.0%   
Profit before tax Rs m5,474285 1,921.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m02,096 0.0%   
Extraordinary Inc (Exp) Rs m0-32 0.0%   
Tax Rs m1,4606 23,932.8%   
Profit after tax Rs m4,0142,343 171.3%  
Gross profit margin %33.66.6 511.7%  
Effective tax rate %26.72.1 1,245.6%   
Net profit margin %23.2185.9 12.5%  
BALANCE SHEET DATA
Current assets Rs m7,6391,689 452.3%   
Current liabilities Rs m2,715486 558.4%   
Net working cap to sales %28.595.4 29.9%  
Current ratio x2.83.5 81.0%  
Inventory Days Days43217 19.9%  
Debtors Days Days7981 97.1%  
Net fixed assets Rs m6,9141,624 425.7%   
Share capital Rs m177534 33.1%   
"Free" reserves Rs m11,4425,960 192.0%   
Net worth Rs m11,7217,404 158.3%   
Long term debt Rs m149104 142.6%   
Total assets Rs m14,8148,010 184.9%  
Interest coverage x112.9950.7 11.9%   
Debt to equity ratio x00 90.1%  
Sales to assets ratio x1.20.2 741.2%   
Return on assets %27.429.3 93.8%  
Return on equity %34.231.6 108.2%  
Return on capital %46.531.3 148.7%  
Exports to sales %55.12.9 1,873.4%   
Imports to sales %6.028.9 20.8%   
Exports (fob) Rs m9,52737 25,679.5%   
Imports (cif) Rs m1,038364 285.3%   
Fx inflow Rs m10,42237 28,091.1%   
Fx outflow Rs m1,678365 459.9%   
Net fx Rs m8,744-328 -2,667.0%   
CASH FLOW
From Operations Rs m3,264346 944.4%  
From Investments Rs m-2,093-48 4,396.8%  
From Financial Activity Rs m-1,186-301 393.9%  
Net Cashflow Rs m-15-3 493.3%  

Share Holding

Indian Promoters % 73.8 64.0 115.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 0.2 775.0%  
FIIs % 7.6 9.7 78.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 26.1 65.1%  
Shareholders   20,968 54,701 38.3%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   ELDER PHARMA  FDC LTD.  SHASUN PHARMA  FRESENIUS KABI ONCO.  TTK HEALTHCARE  

Compare AJANTA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Feb 19, 2018 03:37 PM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS